share_log

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

Benzinga ·  Nov 18 20:18
REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment